Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Propanc Biopharma highlighted new preclinical data for its lead candidate PRP in pancreatic ductal adenocarcinoma, showing greater than 90% mean tumor growth inhibition versus vehicle (p < 0.001) and a median overall survival extension of more than 2.5-fold versus controls in animal models. PRP also reduced liver and peritoneal metastases, remodeled the tumor microenvironment, and re-sensitized chemo-resistant PDAC cells to gemcitabine plus nab-paclitaxel. Unlike newly FDA-approved daraxonrasib (Revolution Medicines), PRP targets EMT, cancer stem cells, and fibrosis rather than RAS signaling, and is not RAS-genotype restricted.
Key figures
- Drug Name
- PRP (trypsinogen + chymotrypsinogen, 1:6)
- Phase Of Trial
- Phase 1b first-in-human planned Q1 2027
- Phase 1b enrollment
- up to 50 patients
- Tumor growth inhibition
- >90% mean vs vehicle (p < 0.001)
- Median survival extension
- >2.5-fold vs controls in animal models
- Revolution daraxonrasib mos
- 13.2 vs 6.6-6.7 months (Phase 3 RASolute 302)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.